MSC-1 (anti-LIF mAb)

About Sorrento Therapeutics

Sorrento Therapeutics' mission is to apply cutting-edge science to develop innovative therapies for cancer, pain, and COVID-19. The company has historically grown through an aggressive acquisition strategy, amassing a diverse toolkit of technology platforms including a fully human antibody library, CAR-T, oncolytic viruses, and non-opioid pain delivery. Despite building an extensive pipeline, Sorrento faces severe financial distress, having filed for Chapter 11 bankruptcy in February 2023 to facilitate a strategic restructuring while attempting to advance key clinical assets.

Therapeutic Areas

Other Metastatic solid tumors Drugs